Adderall hits Shire sales
July 30, 2013Sales and Marketing Adderall, Shire, Vyvanse, ldx
Falling sales of Adderall XR have hit Shire in the second quarter of the year, with the ADHD drug dropping …
January deadline for Pfizer restructure
July 30, 2013Research and Development, Sales and Marketing Pfizer, patent, restructure
Pfizer is to restructure operations from January 2014 in a bid to make its business more responsive to patient and …
Nearly all UK men survive testicular cancer
July 30, 2013Research and Development, Sales and Marketing
Survival for testicular cancer has risen by almost 30% in the last 40 years, with nearly all men now beating …
Perrigo pays $8.6 billion for Elan
July 30, 2013Research and Development, Sales and Marketing Elan, Perrigo, Tysabri
Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a bitter takeover battle that has …
Aesica appoints Chris Gowland to the Board
July 30, 2013Manufacturing and Production, Research and Development, Sales and Marketing Aesica, Chris Gowland
Contract development and manufacturing organisation Aesica has appointed Chris Gowland to the newly formed position of chief operating officer. As …
FDA clarifies import rules for ‘pre-launch’ medicines
July 29, 2013Manufacturing and Production Draft Guidance, FDA, pre launch, pre-launch
New draft guidance on the import of unapproved medicines in anticipation of approval in the US has been published by …
Patients and profits – time for new priorities
July 29, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, McConaghie, andrew, pharma, profits
Pharmaceutical journalists don’t retire, they just go off patent. Well, I’m not retiring as such, but after ten years as …
EMA: no cancer risk from GLP-1s
July 29, 2013Research and Development, Sales and Marketing Cancer, EMA, GLP-1s
One of the European Medicines Agency’s key advisory groups has decided that concerns over an increased cancer risk with some …
AZ and BMS go for second Forxiga submission
July 29, 2013Sales and Marketing AZ, BMS, FDA, Forxiga
AstraZeneca and partner Bristol-Myers Squibb have resubmitted their diabetes drug Forxiga to the FDA 18 months after it was rejected …
Boehringer nears European approval for first cancer drug
July 29, 2013Sales and Marketing Boehringer, Cancer, FDA, afatinib
Boehringer’s first cancer drug is just months away from being approved in Europe after a committee for the EMA gave …
PCI hires associate director of Clinical Trials
July 29, 2013Manufacturing and Production, Research and Development, Sales and Marketing
Pharma packaging and clinical trials services firm PCI has appointed Tim Roberts as an associate director of Clinical Trials.The changes …
Contract research news in brief
July 26, 2013Research and Development Ascendancy Healthcare, CRO Solutions, Clinical Research Advantage, ResearchDx, SPS Pharma Services, VxP Pharma
Quintiles wins multi-year contract in China, CRO Solutions sets up niche subsidiary and CRA buys CNS unit, plus relocations for …
Dementia project pays out £50 million
July 26, 2013Medical Communications, Sales and Marketing Jeremy Hunt, dementia
Over a hundred hospitals and care homes across England have been awarded a share of a £50million fund to help …
Sharp fall in sales for Bristol-Myers Squibb
July 26, 2013Sales and Marketing Avapro, BMS, Plavix, Q2
Bristol-Myers Squibb has seen a fall in sales over the past three months as it struggles with major patent losses. …
Lilly beats estimates with solid Q2 performance
July 26, 2013Sales and Marketing Q2, cymbalta, lilly, zyprexa
Lilly posted a healthy set of financials at the end of July as the company looks to keep its growth …
Teva and Lonza abandon biosimilars joint venture
July 26, 2013Manufacturing and Production, Research and Development CMO, Levin, Lonza, Teva, biosimilars
Escalating costs have led Teva and contract manufacturing organisation (CMO) Lonza to abandon a joint venture set up in 2009 …
Two non-executive directors join NICE Board
July 26, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing DoH, NICE, finbarr martin, mumford
The Department of Health has announced that two new non-executive directors will join the National Institute for Health and Care …
Strong growth for Roche in latest results
July 25, 2013Sales and Marketing Alexion, Q2, Rituxan, Roche
Roche has seen strong sales growth in the past six months as it lines up new products to replace its …
UK rejects meningitis B vaccine Bexsero
July 25, 2013Sales and Marketing Bexsero, Novartis, Vaccine, meningitis b
The UK government’s department for vaccinations has stunned observers by failing to back the world’s only vaccine for meningitis B. …
Actions in China ‘shameful’ says GSK boss
July 25, 2013Medical Communications, Sales and Marketing China, GSK, Witty, bribery
GlaxoSmithKline has admitted that allegations of corruption at its China business are ‘shameful’ and will seek out its cause. Speaking …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
